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ABSTRACT
Objective: As a marker for Hepatocellular Carcinoma (HCC), Protein Induced by Vitamin K Absence II
(PIVKA-II) seems to be superior to alpha fetoprotein (AFP). To better characterize the role of PIVKA-II,
both AFP and PIVKA-II have been measured in Italian patients with diagnosis of HCC compared with
patients affected by non-oncological liver pathologies.
Materials and methods: Sixty serum samples from patients with HCC, 60 samples from patients with
benign liver disease and 60 samples obtained from healthy blood donors were included in the study.
PIVKA-II and AFP were measured by LUMIPULSEVR G1200 (Fujirebio-Europe, Belgium). We considered as
PIVKA-II cutoff 70 mAU/ml (mean þ3SD) of the values observed in healthy subjects.
Results: The evaluation of PIVKA-II showed a positivity of 70% in patients with HCC and 5% in patients
with benign diseases (p< 0.0001) whereas high levels of AFP were observed in 55% of HCC patients
and in 47% of patients with benign diseases. The combined Receiver Operating Characteristic (ROC)
analysis of the two analytes revealed a higher sensitivity (75%) compared to those observed for the
individual biomarkers. In conclusion, we demonstrate that as a marker for HCC, PIVKA-II is more specific
for HCC and less prone to elevation during chronic liver diseases.
Conclusions: The combination of the two biomarkers, evaluated by the ROC analysis, improved the
specificity compared to a single marker. These data suggest that the combined analysis of the two
markers could be a useful tool in clinical practice.
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Introduction
Worldwide, the hepatocellular carcinoma (HCC) is the eighth
most common type of solid cancer and the third most com-
mon cause of cancer-related deaths. The deaths attributed to
this form of cancer are a million a year with a mortality
around 94%.[1]
For the diagnosis of HCC, alpha fetoprotein (AFP) is the
most commonly used biomarker. Many studies suggest that
the persistent high values of AFP should be evaluated as a
risk factor for developing HCC.
In virtue of this, AFP has been considered for a long time
as a good biomarker to identify subjects at high risk for
HCC.[2–4]
However, like many other biomarkers, AFP is not tumor-
specific, but is produced and released from the liver tissue in
physiological conditions and in the presence of various onco-
logical and non-oncological diseases. It is well known that
AFP may occasionally be produced in significant quantities
even by other different organs or tissues than the liver.[5–7]
The AFP diagnostic sensitivity for early-stage HCC is only
48%,[8] and therefore, according to the recent guidelines, AFP
is not recommended for HCC surveillance an early
diagnosis.[9]
Because of the poor sensitivity and specificity of AFP, in
the recent years, research has focused on the identification of
new biomarkers that can provide higher sensitivities and
specificities.[10]
Protein Induced by Vitamin K Absence II (PIVKA-II, des-
gamma carboxyprothrombin), is a biomarker identified by
Liebmann some years ago.[11] More recently, PIVKA-II has
been proposed as an emerging circulating marker in HCC.
The first assays were based on the competitive radioimmuno-
assay principle using PIVKA-II polyclonal antibodies. Later,
after the early promising results, in the last two decades,
PIVKA-II has been introduced as a serological marker for HCC
detection.[12,13]
It is extensively recognized that the main role of bio-
markers should be as an early indicator of cancer as well as
an ideal index for the differential diagnosis between benign
or not benign disease. With regard to early and differential
diagnosis of HCC, many studies showed a better specificity of
PIVKA-II in comparison with AFP. Finally, it is important to
highlight that PIVKA-II is a promising biomarker capable of
following the remission of the disease and monitoring the
response to therapy.[14]
To date, PIVKA-II has been mainly investigated in Asian
countries, and inspite of its potential diagnostic and
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prognostic value, knowledge about PIVKA-II in Europe, and
particularly in Italy, remains limited.
To better characterize the role of PIVKA-II in patients with
HCC, we measured PIVKA-II and AFP levels in a group of
patients with diagnosis of HCC compared to a group of
patients affected by Hepatitis C Virus (HCV), Hepatitis B Virus
(HBV) and space occupying lesion (SOL).
Patients and methods
Patients
All subjects included in the study were patients admitted to
our laboratory. All patients and subjects gave their informed
consent for the investigation. For this study, we analyzed 180
serum samples with following characteristics:
a. Sixty serum samples from patients with HCC (age range:
39–86; 41 males, 19 females);
b. Sixty serum samples from patients with benign liver dis-
ease: HCV, HBV and SOL (age range: 26–84, 23 males, 37
females);
c. Sixty serum samples obtained from a population of
healthy blood donors (age range: 22–74, 26 males, 34
females).
Sample preparation
All sera were acquired following a standard collection proto-
col. Briefly, samples were collected in a Red Top Vacutainer,
clotted 60–90min and centrifuged for 10min at 1300 g. The
serum fractions were aliquoted and stored at80 C until
analysis.
Biomarker assays
The levels of PIVKA-II and AFP were measured by LUMIPULSEVR
G1200 (Fujirebio-Europe, Belgium).[15] All assays were per-
formed according to the manufacturers’ instructions.
LUMIPULSEVR G1200 (Fujirebio-Europe, Belgium) is an assay sys-
tem for the quantitative measurement in serum or plasma
specimens based on chemiluminescent enzyme immunoassay
(CLEIA) technology by a two-step sandwich in immunoreaction
cartridges (Fujirebio Europe NV, Belgium). This assay makes
use of monoclonal antibody-coated beads and alkaline phos-
phatase (ALP)-labeled monoclonal antibody. In the first reac-
tion, the analyte specifically binds to monoclonal antibody on
the particles forming antigen–antibody immunocomplexes. In
the second reaction, ALP-labeled monoclonal antibody binds
to the analyte of the immunocomplexes. Then the adamantyl-
1,2-dioxetane phosphate (AMPPD) contained in the substrate
solution is dephosphorylated by the catalysis of ALP indirectly
conjugated to the particles. A luminescent signal is generated
by the cleavage reaction of dephosphorylated AMPPD and
reflects the amount of antigen in the sample.
According to the manufacturer’s indications, expected nor-
mal values are, for AFP in a range of 1.7–7.4 ng/mL and for
PIVKA-II in a range of 16–48 mAU/mL.
Regarding the clinical cut-points of PIVKA-II, according to
literature discordant between Japanese and American studies,
we defined the cutoff on our population.
Statistical analysis
Sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) of each biomarker were calcu-
lated. Differences in accuracy of the two biomarkers between
the HCC and the other benign pathologies were evaluated by
the Chi-squared test. The diagnostic accuracy of the assays
was assessed by estimation of the Receiver Operating
Characteristic (ROC) curve for HCC cases versus benign liver
diseases using MedCalc V 4.30 Software (Italy).
Results
Definition of normal levels in our healthy population: PIVKA-II
Sixty blood donors were included in this study. These sam-
ples were evaluated thanks to a collaboration with the Blood
Bank of the Policlinico Umberto I. On the basis of these
results, we considered as cutoff 70 mAU/mL (35.5 ± 11.5;
mean ±3 SD).
To note that none of the healthy subjects showed PIVKA-II
values above the limit of positivity. We observed a highly
statistically significant difference between HCC patients
and patients affected by benign liver disease (p< 0.0001)
(Figure 1).
We observed high levels of AFP in 55% of HCC patients
and in 47% of patients with benign diseases, while it was 5%
in the control group (Figure 2).
No statistically significant difference was observed
between the patients with HCC versus those with benign
disease.
The PIVKA-II specificity and sensitivity studied in the two
selected groups of patients showed, by statistical analysis,
that the area under the ROC curve was 0.814 (95% CI
0.735–0.89).
The statistical analysis for AFP in the same two group of
patients showed that the area under the ROC curve was
0.618 (95% CI 0.516–0.720).
The PIVKA-II ROC curve analysis showed, that the best spe-
cificity (0.90) and sensitivity (0.60) are obtained with a cutoff
47 mAU/mL, with a PPV of 0.86 and a NPV of 0.69 (Figure 3).
Whereas the AFP ROC curve showed the best specificity
(0.55) and sensitivity (0.55) with a cutoff of 20 mAU/mL, with
both PPV and NPV of 0.55 (Figure 4).
Comparison of the ROC curves of the combination of
PIVKA-II and AFP resulted in the highest sensitivity (75%) and
a specificity of 61%, with PPV and NPV of 62% and 70%,
respectively (Figure 5).
Discussion
HCC is one of the most common cancers worldwide with a
high rate of mortality. Diagnostic surveillance of at-risk
patients is done by ultrasound, sometimes completed with
the measurement of a tumor marker. However, the accuracy
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of ultrasound is operator-dependent and is based on his or
her ability to differentiate HCC from non-neoplastic lesions
such as regenerative nodules.[16]
Recently, tumor biomarkers to detect cancer have helped
in surveillance of high risk patients to screen for disease and
avoid wasting medical resources.[17–19]
Tumor markers are biological substances produced dir-
ectly by the tumor or by non-tumor cells as a response to
the presence of a tumor. They are usually detected in a
solid tumor, in circulating tumor cells in peripheral blood,
in lymph nodes, in bone marrow, or in other body fluids
(urine, stool, ascites).[20] Thus far, more than 20 different
tumor markers have been studied and characterized, but
only few of them have gained a greater importance in clin-
ical routine.
The most widely used biomarker for HCC is serum AFP.
Serum AFP is commonly regarded as a supplementary param-
eter for diagnosis of HCC and a tool for predicting recurrence
and survival. but its clinical use in the management of HCC
patients is limited because AFP often is increased in other
oncologic and inflammatory diseases.[21–25]
Research has been recently focusing on a new biomarker
known as PIVKA-II that may provide superior utility over cur-
rent markers.[22,23]
Figure 1. PIVKA-II: distribution of values of PIVKA-II in healthy subjects, patients with HCC, and benign liver disease (results are expressed as mAU\mL).
Figure 2. AFP: Distribution of values of AFP in healthy subjects, patients with HCC, and benign liver disease (results are expressed as mAU\mL).
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Since Liebman et al. demonstrated PIVKA-II to be a useful
marker for HCC diagnosis, many studies have compared
PIVKA-II and AFP.[24,26–28]
A PIVKA-II level of 40 mAU/mL is now commonly used as
the cutoff value for diagnosis of HCC.
Many studies have been reported to evaluate the useful-
ness of PIVKA-II for HHC diagnosis. Regrettably the sensitivity
and sensitivity described by these studies were rather differ-
ent. The most important reason for these differences involves
the use of different PIVKA-II cutoff in each studies. In particu-
lar, the most significant difference in marker cutoff is
observed in the studies conducted on the Asian population
than the American population.[8,14] Since, in the literature
there is disagreement regarding the cutoff to be taken into
consideration, we felt it appropriate to evaluate a new cutoff
on our population. On the basis of our data, we considered
as cutoff a PIVKA-II level of 70 mAU/mL (mean ±3SD). In par-
ticular with this cutoff we observed that PIVKA-II is positive in
a high proportion (70%) in HCC patients and in only 5% of
patients with inflammatory diseases, while AFP is elevated in
55% of HCC and 47% of patients with benign diseases show
fluctuating levels of AFP.
In this study, we demonstrated for the first time, in a
cohort of Italian patients that PIVKA-II is more accurate than
AFP in differentiating patients with HCC from those with non-
malignant chronic liver disease.
In particular, our results showed that as a marker for
HCC, PIVKA-II may be superior to AFP. PIVKA-II is more spe-
cific to HCC and less prone to elevation during chronic
liver disease.
Figure 3. ROC analysis of PIVKA-II.
Figure 4. ROC analysis of AFP.
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The combination of two biomarkers as suggested by ROC
curve analysis, indicates for the best discrimination between
benign and HCC diseases to use for PIVKA-II 47 mAU/mL as
cutoff. This finding is in agreement with the instruction of the
manufacturer. Our next goal will be the evaluation, by pro-
spective studies in a much larger population of patients
the effective capacity to make differential and early
diagnosis HCC.
This study suggests that the combined analysis of the two
markers could be a useful tool in clinical practice. This could
also have benefits on ‘‘health economics’’ by reducing the
number of investigations necessary for a proper diagnosis
and further clinical management of patients with HCC.
A recent study that compared AFP against PIVKA-II, dem-
onstrated that AFP, the best prognostic single marker for the
diagnosis of HCC is in disagreement with our results.[29]
Interestingly, this study has used PIVKA-II ELISA KIT tech-
nique that in comparison with PIVKA-II chemiluminescent
enzyme immunoassay (CLEIA) technology shows less sensitiv-
ity and in general inferior performances.
In addition a high percentage of HCC patients enrolled in
this study were infected with HBV virus, nevertheless some
researchers suggests that PIVKA-II provides substantial added
value to the HCC with non-viral etiologies.[30]
Although a high percentage of positivity for PIVKA-II was
found among patients suffering from HCC and a low positiv-
ity percentage in other pathologies, it was however of inter-
est to see that seven patients affected by other pathologies
were also positive for PIVKA-II.
This finding is in agreement with other studies that show
occasionally aberrant elevation of PIVKA-II in patients with
alcoholic cirrhosis, obstructive jaundice or vitamin K
deficiency.[31]
Our results are very encouraging but there are several
important limitations in our study. The sample size was small
and the tumor staging was not well known and for these rea-
sons we consider it as a preliminary study. More large scale
and multicenter studies are needed to assess the clinical use-
fulness of PIVKA-II in the diagnosis and clinical management
of HCC patients.
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